Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 54, Issue 22, Pages 7772-7783Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm200893p
Keywords
-
Categories
Ask authors/readers for more resources
A metabolism-based approach toward the optimization of a series of N-arylsulfonamide-based gamma-secretase inhibitors is reported. The lead cyclohexyl analogue 6 suffered from extensive oxidation on the cycloalkyl motif by cytochrome P450 3A4, translating into poor human liver microsomal stability. Knowledge of the metabolic pathways of 6 triggered a structure-activity relationship study aimed at lowering lipophilicity through the introduction of polarity. This effort led to several tetrahydropyran and tetrahydrofuran analogues, wherein the 3- and 4-substituted variants exhibited greater microsomal stability relative to their 2-substituted counterparts. Further reduction in lipophilicity led to the potent gamma-secretase inhibitor and 3-substituted oxetane 1 with a reduced propensity toward oxidative metabolism, relative to its 2-substituted isomer. The slower rates of metabolism with 3-substituted cyclic ethers most likely originate from reductions in lipophilicity and/or unfavorable GYP active site interactions with the heteroatom. Preliminary animal pharmacology studies with a representative oxetane indicate that the series is generally capable of lowering A beta in vivo. As such, the study also illustrates the improvement in druglikeness of molecules through the use of the oxetane motif.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available